Optimising the dosing of medicines for neonates and children remains a challenge. The importance of pharmacokinetic (PK) and pharmacodynamic (PD) research is recognised both in medicines regulation ...
(3) Emricasan is an irreversible pan-caspase inhibitor, which is currently in a phase 2 clinical trial to test its efficacy in treating liver injury and fibrosis, although its clinical trial results ...